ArticlePNAS nexus2025
Dynamic claw of dengue protease unveils druggability potential with high affinity allosteric inhibitors.
Article in PNAS nexus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several enzymes receive functional signals from allosteric site to the active site through conformational dynamics while domain dynamics can also play a significant role. Current investigation identifies a claw-like regulatory region near the active site of dengue protease, which remains in dynamic equilibrium as active (open) and inactive (closed) forms. Enhanced sampling with metadynamics showed that the flexibility of the T[RK][SN]G loop of the claw region is crucial for the protease activity as it helps in the opening of the claw-like structure near the active site, and allows the C-terminal hydrophilic part of NS2B cofactor to enter the claw and transform the protease into its active conformation. Binding kinetics and thermodynamics studies further reveal that allosteric modulator epigallocatechin-3-gallate (EGCG) binds to the enzyme in a biphasic manner and disrupts the active/inactive conformational dynamics and locks the enzyme in an inactive conformation. The inhibitor binding in this region introduces an energy barrier in the free energy landscape of NS2B cofactor binding. In the stronger mode, EGCG could directly bind into the claw, induces conformational changes, locking the dynamic loops in a closed position, preventing NS2B binding and rendering the enzyme inactive. Whereas in the weaker mode, EGCG binds to the T[RK][SN]G loop and perturbs its flexibility driving the claw structure into a more closed conformation and maintaining the protease in an inactive state. The understanding of the mechanism, therefore, would help researchers design more potent inhibitors targeting dengue protease and homologous enzymes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.